Close Menu

In Silico: Oct 1, 2002

Premium

www.GenomeWeb.COM Daily

 

Tool Talk

 

As big pharma’s product pipeline continues to wither, the role of genomics tools and data providers becomes increasingly uncertain. Will the pressure on pharma firms mean that genomic companies can expect an increase in new-technology orders? Or will pharma’s revenue woes mean increased spending becomes foolish?

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

NPR reports the US Food and Drug Administration has approved a treatment for a genetic disorder that causes rapid aging.

Late-stage testing indicates the AstraZeneca and Oxford University SARS-CoV-2 vaccine can have up to 90 percent efficacy, the Associated Press reports.

ScienceInsider reports Nature Communications is reviewing a paper on mentorship following social media criticism arguing it is sexist.

In PLOS this week: method to account for sequencing errors in phylogenies, study of influenza A in Switzerland, and more.